Self-Monitoring of Blood Glucose in People with Type 2 Diabetes: Canadian Diabetes Association Briefing Document for Healthcare Providers

Miller, David S.; Berard, Lori; Cheng, Alice; Hanna, Amir; Hagerty, Donna; Knip, Aileen; McDougall, Peter; Woo, Vince

doi:10.1016/s1499-2671(11)54003-1

Cited by 14 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Active Intervention: All patients who develop hyperglycemia should be advised to drink plenty of water, exercise regularly, reduce dietary carbohydrates and sugar, and use frequent glucose self-monitoring (frequency is individualized, but can be 2 or more times daily) 34 . Clinical management depends on the severity of hyperglycemia.…”

Section: Early Recognition and Frequent Monitoringmentioning

confidence: 99%

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

et al. 2015

View full text Add to dashboard Cite

The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment strategy. Everolimus, an mtor inhibitor, is the first of this class of agents approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Everolimus has been associated with significant improvements in progression-free survival; however, it is also associated with increased toxicity related to its specific mechanism of action. Methods: A comprehensive review of the literature conducted using a focused medline search was combined with a search of current trials at http://ClinicalTrials.gov/. Summary tables of the toxicities of the various classes of PI3K/Akt/mTOR inhibitors were created. A broad group of Canadian health care professionals was assembled to review the data and to produce expert opinion and summary recommendations for possible best practices in managing the adverse events associated with these pathway inhibitors. Results: Differing toxicities are associated with the various classes of PI3K/Akt/mTOR pathway inhibitors. The most common unique adverse events observed in everolimus clinical trials in breast cancer include stomatitis (all grades: approximately 60%), noninfectious pneumonitis (15%), rash (40%), hyperglycemia (15%), and immunosuppression (40%). To minimize grades 3 and 4 toxicities and to attempt to attain optimal outcomes, effective management of those adverse events is critical. Management should be interdisciplinary and should use approaches that include education, early recognition, active intervention, and potentially prophylactic strategies. Discussion: Everolimus likely represents the first of many complex oral targeted therapies for the treatment of breast cancer. Using this agent as a template, it is essential to establish best practices involving and integrating multiple disciplines for the management of future PI3K/Akt/mTOR signalling pathway inhibitors.

show abstract

Section: Early Recognition and Frequent Monitoringmentioning

confidence: 99%

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Apparently, the alternatives to SMBG are not convincing, and this is why both patients and physicians oppose the threat of losing SMBG as treatment support. 20,21 Since the very beginning of modern diabetes therapy, the discrepancy between blood glucose and urine glucose was detected and discussed, e.g., in the 1919 work of Williams and Humphreys. 22 This effect is caused by multiple influences such as drinking, eating, physical activity, and the simple fact that the glomerular filtration rate varies.…”

Section: Self-monitoring Of Blood Glucose a Physician's Dilemmamentioning

confidence: 99%

Self-Monitoring of Blood Glucose: One STeP Forward?

Schramm

2012

J Diabetes Sci Technol

View full text Add to dashboard Cite

show abstract

“…In contrast, a guidance document published by the Canadian Diabetes Association (CDA) suggested that the number of SMBG tests be individualized for patients with type 2 diabetes using insulin; 15 test strips per month should be available for patients taking antidiabetes drugs, who have lower risks for hypoglycemia, and 30 test strips per month should be available for for patients taking antidiabetes drugs, who have higher risks for hypoglycemia (i.e. sulfonylureas, meglitinides) (12).…”

Section: Introductionmentioning

confidence: 99%

“…In order to encourage appropriate use of these products and to decrease expenditures, policies of quantity limits for BGTS have been suggested and have been implemented in some jurisdictions across Canada. For example, in 2013, the Ontario Ministry of Health and Long-Term Care's public drug program implemented test strip quantity limits aligned with the CDA's guidance (12,14). A similar policy was subsequently adopted by the British Columbia and Saskatchewan public drug plans in 2015.…”

Section: Introductionmentioning

confidence: 99%

Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada

Knowles

Lee

Paterson

et al. 2017

Canadian Journal of Diabetes

View full text Add to dashboard Cite

show abstract

Self-Monitoring of Blood Glucose in People with Type 2 Diabetes: Canadian Diabetes Association Briefing Document for Healthcare Providers

Cited by 14 publications

References 2 publications

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Self-Monitoring of Blood Glucose: One STeP Forward?

Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada

Contact Info

Product

Resources

About